Annual screening with CA-125 and transvaginal ultrasound has a high sensitivity and positive predictive value, but the majority of cancers detected in this manner are stage III or higher, and an annual screening is interval associated with a poor overall 10-year survival in the carriers of germline BRCA1/BRCA2 variants [96]. The gene discussed is BRCA2; the disease is cancer.